Aastrom Reports Interim Results From Critical Limb Ischemia Trial

(Stem Cells News image)

Aastrom Biosciences, Inc. (Nasdaq:ASTMD), a leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today reported results from a planned interim analysis of the company’s multi-center, randomized, double-blind, placebo-controlled U.S. Phase 2b clinical trial designated RESTORE-CLI. According to the interim analysis the safety profile was similar between the treatment and placebo arms.

Based on a composite efficacy endpoint assessing time to treatment failure (including major amputations, wound size and gangrene), Aastrom’s autologous vascular repair cells (VRCs) were more effective than placebo (P<0.05). Other clinically meaningful endpoints (e.g., major amputation rate, complete wound closure) approached but did not reach statistical significance at interim analysis. Forty-six critical limb ischemia (CLI) patients who had at least 6-month follow up, including 33 patients with 12-month follow up, contributed to the interim analysis.

Aastrom’s RESTORE-CLI trial is the largest blinded, randomized cell therapy study currently being conducted for CLI. The interim analysis was planned to assess performance of the cell therapy and to help plan further studies. Based on the interim findings, Aastrom will conclude enrollment of new patients in order to complete the study as soon as possible, and begin planning and discussions with the U.S. Food and Drug Administration for pivotal clinical trials with VRCs.

“These encouraging data have demonstrated an excellent safety profile and indicate that Aastrom’s autologous cellular therapy could be an important addition to what is now a limited range of treatment options for patients with CLI,” said Anthony J. Comerota, MD, FACS, FACC, director of the Jobst Vascular Center in Toledo, OH.

CLI is typically identified as the end stage of peripheral arterial disease. People with CLI face a high risk of amputation and in some cases death. Approximately 1 million patients in the U.S. suffer from CLI. The disease results in more than 160,000 amputations each year.

“Based on these results, we can now move ahead with plans to advance this program into Phase 3 clinical testing,” said Tim Mayleben, president and CEO of Aastrom. “We look forward to presentation of the full data at an appropriate medical meeting and initiating the next phase of testing as soon as possible.”

Aastrom will host an investor conference call today at 9:00 am ET to discuss these results. Interested parties should call (877) 407-9210 (international: (201) 689-8049) 15 minutes before the start of the call and identify themselves as registrants of the ‘Aastrom Conference Call’. The call will be simulcast on the web at http://www.investorcalendar.com/IC/CEPage.asp?ID=155867 and archived for 90 days at the same website.

from http://www.aastrom.com/releasedetail.cfm?ReleaseID=446720

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.